# UPMC Hillman Cancer Center

Source: https://onco.cc/institutions/upmc-hillman/  
OnCo record `upmc-hillman` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UPMC Hillman is Pittsburgh's NCI comprehensive centre; Bernard Fisher ran the NSABP breast trials here, Yuan Chang and Patrick Moore discovered Kaposi sarcoma herpesvirus and Merkel cell polyomavirus, and its LAG-3 biology underpins the melanoma drug relatlimab.

## Summary

NCI comprehensive since 1990, UPMC Hillman spans western Pennsylvania through UPMC's network. Bernard Fisher led the NSABP from Pittsburgh, proving with B-06 that lumpectomy plus radiation equals mastectomy and with P-1 that tamoxifen prevents breast cancer; NSABP lives on within NRG Oncology. Yuan Chang and Patrick Moore discovered Kaposi sarcoma herpesvirus in 1994 and Merkel cell polyomavirus in 2008. Dario Vignali's LAG-3 biology underpins relatlimab, Hassane Zarour and Diwakar Davar showed faecal microbiota transplant can overcome anti-PD-1 resistance in melanoma, and Greg Delgoffe studies T-cell metabolism in tumours. The centre also has a large head and neck cancer immunotherapy programme.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: University of Pittsburgh Cancer Institute
- City: Pittsburgh, PA, US
- Type: cancer-center
- NCI designation: comprehensive
- Website: https://hillman.upmc.com

## Sources

- UPMC Hillman Cancer Center: https://hillman.upmc.com
- Clinical trials: https://hillman.upmc.com/research/clinical-trials

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Kaposi sarcoma](https://onco.cc/cancers/kaposi-sarcoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/)
- technologies: [CyberKnife robotic radiosurgery](https://onco.cc/technologies/cyberknife/), [Gamma Knife](https://onco.cc/technologies/gamma-knife/), [Microbiome modulation to unlock immunotherapy](https://onco.cc/technologies/microbiome-modulation-io/), [Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)](https://onco.cc/technologies/radiosurgery-srs/)
- targets: [LAG-3](https://onco.cc/targets/lag3/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Relatlimab + nivolumab](https://onco.cc/drugs/relatlimab-nivolumab/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- companies: [NRG Oncology](https://onco.cc/companies/nrg-oncology/)
- people: [Jason J. Luke](https://onco.cc/people/jason-luke/), [John M. Kirkwood](https://onco.cc/people/john-kirkwood/)
- key papers: [Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma](https://onco.cc/key-papers/paper-singhi-alk-rearrangements-pancreatic-jnccn-2017/), [Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers](https://onco.cc/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/), [The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival](https://onco.cc/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)

---
JSON: https://onco.cc/api/v1/entities/upmc-hillman.json